Legislators returned to Washington to debate issues of public policy, including a proposal to provide a low-cost drug benefit for Medicare beneficiaries.
With the president's impeachment behind them, legislators returned to Washington to debate issues of public policy, including a proposal to provide a low-cost drug benefit for Medicare beneficiaries.
Lack of prescription drug coverage is an often-criticized flaw of Medicare. Senior citizens are the recipients of roughly 40% of all prescriptions in the United States, but they receive few, if any, breaks on the costs of filling those prescriptions.
Sen. John Breaux (D-LA) has presented a plan that would attempt to address that problem. Breaux, the chairman of the National Bipartisan Commission on the Future of Medicare, proposes allowing more private health care plans to participate in Medicare and granting senior citizens government-subsidized premium support which they could apply toward participation in a health plan that provides prescription drug coverage. Breaux's premise is that greater competition among private health care plans will lower the overall costs of Medicare.
In early February, Breaux submitted his proposal to the Congressional Budget Office for review. On Feb. 18, the office responded that it needed more details in order to evaluate long-term savings. They promised to review it again on Feb. 24. Analysis by the National Bipartisan Commission on the Future of Medicare suggested that the plan could reduce Medicare spending by 25% by 2030.
Breaux's plan received cautious support from the pharmaceutical industry. Jeff Trewhitt, spokesperson for Pharmaceutical Research and Manufacturers of America, the industry's Washington-based lobbying arm, said: "This Senate bill - although not perfect - makes sense. It seems to be a legitimate approach to processing 300 million claims per year."
This stance was in stark contrast to the association's reaction to The Prescription Drug Fairness Act for Seniors, a bill drafted by Rep. Tom Allen (D-ME.)
Allen's bill proposed that the government require pharmaceutical companies to sell medicines to seniors at prices similar to those pitched to the manufacturers' favored buyers, such as health maintenance organizations and the federal government. Typically, those prices are about half as much as retail.
PhRMA and numerous patient advocacy associations shot down Allen's bill immediately, complaining that government price controls would hurt the research and development of new medicines. Also, PhRMA said, the bill guarantees lower prices to pharmacies and assumes that those savings would be passed on to senior citizens, but the bill does not guarantee it.
"We have always said there is a right way to do something and a wrong way to something," Trewhitt said. "We acknowledge that there is a problem and that there are ways to resolve it, but a mandatory program with mandatory price rebates is not the way to do it."
Breaux's plan, on the other hand, leaves pricing control to the competitive health care marketplace, a fact not lost on or unappreciated by pharmaceutical companies.
"The market does emphasize cost containment and discounts, but these things are negotiated," said Trewhitt. "When a company argues the benefits of putting drugs on formularies, they can argue the research and development costs."
The research and development card is one that apparently has high value with consumers and patient advocacy groups, as well as with PhRMA. The Seniors Coalition, based in Fairfax, VA, said "the pharmaceutical industry has made available contributions to enhance the quality of life and protect patients from needless pain and suffering," and warned that other countries that had experimented with price control "literally stifled innovation to encourage innovation and research into new drug therapies."
The Cancer Research Foundation of America, the Kidney Cancer Association, the International Patient Advocacy Association and the Healthcare Leadership Council also chimed in that they opposed any legislation imposing price controls that would slow research and development efforts.
"For centuries, governments have imposed price controls with the same good intentions: protecting consumers," said Pamela Bailey, president of the Healthcare Leadership Council. "And for centuries, price controls have had the same dismal results: shortages, rationing, fewer consumer choices, less innovation and lower quality."
"Government price controls over pharmaceuticals were soundly defeated when part of the Clinton health plan in 1993," Bailey added. "They should be soundly rejected now, as well." PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.